Airway response to sirolimus therapy for the treatment of complex pediatric lymphatic malformations.
- Author(s): Alemi, A Sean
- Rosbe, Kristina W
- Chan, Dylan K
- Meyer, Anna K
- et al.
Published Web Locationhttp://dx.doi.org/10.1016/j.ijporl.2015.10.031
Head and neck lymphatic malformations can create airway management challenges requiring tracheotomy. Sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), may inhibit growth of lymphatic malformations. We describe two patients born with large lymphatic malformations with improved airway symptoms following sirolimus therapy. Patient #1 underwent tracheotomy and multi-modal therapy including sirolimus with reduction in airway involvement but regrowth after discontinuation of sirolimus. Patient #2 also experienced a significant response to sirolimus allowing for extubation and discharge without tracheotomy. Early initiation of sirolimus therapy should be considered as a means to avoid tracheotomy in complex head and neck lymphatic malformations.